BioLife Solutions Launches New Corporate Website
PRNewswire-FirstCall
BOTHELL, Wash.

BioLife Solutions Inc. (BULLETIN BOARD: BLFS) , a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells, tissues, and organs, today launched its new corporate website. Researchers, customers, strategic partners, and investors can now access corporate, product, technical, financial and other information at www.biolifesolutions.com.

BioLife's corporate website was developed by Palazzo Intercreative (www.palazzo.com), a Seattle-based multimedia creative agency whose clients include Microsoft, the American Red Cross, the Puget Sound Blood Center, and the Fred Hutchinson Cancer Research Center.

Mike Rice, BioLife chief executive, commented on the creative and design capabilities of the Palazzo team: "We were impressed by Palazzo's knowledge of our industry and business in creating an impactful and useful place for our important audiences. They also designed the website to be consistent with our corporate identity and marketing strategy."

About BioLife Solutions

BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells, tissues and organs. The Company's proprietary HypoThermosol® and CryoStor™ solution platforms are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and formulated to reduce or prevent preservation-induced, delayed-onset cell damage and death. BioLife's enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function. For more information please visit www.biolifesolutions.com.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

  Media Relations:                  Investor Relations:
  Len Hall                          Matt Clawson
  Allen & Caron Inc.                Allen & Caron Inc.
  (949) 474-4300                    (949) 474-4300
  len@allencaron.com                matt@allencaron.com

SOURCE: BioLife Solutions Inc.

CONTACT: Media Relations, Len Hall, len@allencaron.com, or Investor
Relations, Matt Clawson, matt@allencaron.com, both of Allen & Caron Inc.,
+1-949-474-4300, for BioLife Solutions Inc.

We believe the promise of cell and gene therapies starts with the integrity of a single cell

Advancing the future of cell and gene therapy

The human body can heal itself. Cell and gene therapies are designed to augment the patient’s ability to fight disease but only if the living cells behind those therapies remain viable and functional throughout the production processes. At BioLife Solutions, our mission is to protect the integrity of cells and provide trusted tools, services, and expertise that can enable our customers to advance the development and delivery of cell and gene therapies. We believe the future of cell and gene therapies hinges on the integrity of every single cell and we are here to protect that promise.

We understand the technical demands of bioprocessing in this field, and our advanced biopreservation expertise, cell culture optimization products, innovative storage systems, and closed-system manufacturing solutions are designed to enhance process efficiency, maintain cellular viability, and ensure reproducibility at every stage. Whether scaling up from R&D, navigating clinical trials or optimizing cryopreservation protocols for commercial production, we provide the tools and experience to streamline your workflow and safeguard your therapies.

Work with experts who understand your biopreservation challenges

Notch-Right-25px
Notch-Bottom-25px

Collaborative and comprehensive CDMO support

At BioLife Solutions, we partner with leading contract development and manufacturing organizations (CDMOs) to enhance their biopreservation and cell processing capabilities. By providing advanced tools, regulatory support, and process optimization strategies, we empower CDMOs to better serve therapy developers, ensuring quality, consistency, and scalability in cell therapy manufacturing.

Regulatory
readiness

Navigating the complex regulatory landscape of cell and gene therapy requires a proactive approach. BioLife Solutions offers experienced regulatory support to help prepare your biopreservation and cell processing methods to meet global standards. From IND and BLA submissions to compliance with GMP, FDA, and EMA guidelines, our solutions help streamline approval pathways.

Notch-Left-25px
Notch-Bottom-25px

STORE

CellSeal®
CryoCase

Alleviate CGT container challenges like fracture risk, bag burping or high rates of particulates

Notch-Right-25px
Notch-Bottom-25px

Data-driven
decision making

Stay ahead with our comprehensive Evidence Library, a curated collection of scientific publications, white papers, and case studies demonstrating the efficacy of BioLife Solutions’ technologies. Access peer-reviewed research, real-world application data, and expert insights to support your bioprocessing and regulatory strategies.

Insights

May 21, 2025

Designing the Ideal Cryostorage Container for CGT

April 18, 2025

The Cell Summit ’25: A Must-Attend Event for Innovators in Cell & Gene Therapy

March 27, 2025

Optimizing Biopreservation Strategies for Apheresis-Derived Cells in Immunotherapeutic Applications

February 19, 2025

How to prepare early for regulatory submissions from IND to BLA

Preserve, protect and expand cell performance

Mastering
Biopreservation

Ensure Regulatory Submission Readiness

Automate & Close
CGT Processes

Protect & Expand
Cell Performance